evidenced by Spearman correlation coefficients of ≥.50 were hypothesized between IPAQ-LF total or its subscales and the armband to conform convergent construct validity (p<.05 (r=.496, p<.01). No relevant nor significant correlations were found for the other IPAQ-LF subscales. Taken together, no hypothesis could be confirmed. Conclusions: Even at a group level, the convergent construct validity of IPAQ-LF in axSpA was not confirmed. Self-reported PA outcomes may provide important contextual information on PA, but perform poor at quantifying PA levels in axSpA. Future research on a feasible self-reported PA measurement tool for these patients is required.
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evidenced by Spearman correlation coefficients of ≥.50 were hypothesized between IPAQ-LF total or its subscales and the armband to conform convergent construct validity (p<.05 Background: Tofacinitib is an oral Janus Kinase for the treatment for rheumatoid arthritis (RA). The efficacy and safety of tofacitinib in monotherapy or in combination with other DMARDs has been demonstrated in clinical trials. However previous studies had report hematological changes and infections associated to the use of this medication (1, 2); in the European Union (EU) Tofacitinib is an investigational medicine and has not been approved for use because concernings regarding its safety. Objectives: We aim to describe the safety profile of Tofacitinib in patients with RA in in a real-life setting in Bogotá, Colombia. Methods: During 2015-2016 we followed patients from a RA specialized center in Colombia receiving Tofacinitib. Patients were treated with therapeutic goals T2T and a multidisciplinary approach. Adverse events were classified according the Common Terminology Criteria for Adverse Events (CTCAE) of the World Health Organization. Descriptive epidemiology for continuous variables, measure of central tendency and dispersion for qualitative and categorical variables through percentages and averages were calculated. Results: We included 56 patients receiving tofacitinib, 80% were woman, 20% men. Mean age was 60±11 years. The mean time with RA was 17 months ± 12. 70% of patients had comorbidities; the most frequent comorbidity was hypertension 30%, followed by osteoporosis 25%, 7.5% Sjogren's syndrome, 7.5% diabetes mellitus among others. 70% of patients received some Anti-TNF drugs before using Tofacitinib; average time receiving tofacitinib was 33±32 weeks, mean DAS28 was 3.7±1.6. Regarding safety profile 10 of 56 patients presented any adverse event. 5 were mild, 4 moderate and 1 severe (1.7%). Diarrhea 1, Infections 1, Abdominal discomfort 3, Mouth papules 1, Rash 1, Sinusitis 1, Headache 1, Folliculitis 1 and Pancreatitis 1. Conclusions: Tofacitinib is a safe and effective medication for patients with AR; regarding safety the proportion of patients with any AE is lower compared to previous studies, but the type of events were similar to clinical trials (1); none of Abstract FRI0752-HPR - 
